Meta- analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to reduce both the risk of severe asthma exacerbation and healthcare use .
Children and people with frequent severe asthma exacerbations were under-represented ; additional primary trials are needed to establish whether vitamin D can reduce the risk of severe asthma exacerbation in these groups
BACKGROUND Several clinical trials of vitamin D to prevent  asthma exacerbation  and improve  asthma control  have been conducted in children and adults , but a meta- analysis restricted to double-blind , r and omised , placebo-controlled trials of this intervention is lacking .
OBJECTIVES To evaluate the efficacy of administration of vitamin D and its hydroxylated metabolites in reducing the risk of severe asthma exacerbations ( defined as those requiring treatment with systemic corticosteroids ) and improving asthma symptom control .
Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study
Objective : To assess the pulmonary function and quality of life in asthma patients receiving vitamin D3 supplementation with inhaled budesonide and formoterol . Material s and Methods : This was a double blinded , r and omized , comparative study . Patients were recruited as per the study criteria and r and omized into two groups :  usual care group ( n = 69 ) patients  received budesonide ( 800 μg ) with formoterol ( 24 μg ) and  intervention care group ( n = 72 ) patients  received vitamin D3 ( 1000 IU ) supplementation along with budesonide ( 800 μg ) plus formoterol ( 24 μg ) for a period of 6 months . Results : A total of 140 patients completed the study . Significant within-group improvement and non-significant between-group improvement is observed with respect to FEV1 . In terms of health-related quality of life , within-group comparison revealed a significant ( P < 0.05 ) improvement in all the domains of SGRQ . However , between-group comparisons showed statistically significant ( P < 0.05 ) improvement in symptom , impact and total scores . Conclusion : On the basis of our findings , we conclude that supplementation of vitamin D3 is effective in improving the quality of life rather than pulmonary function in severe asthmatics . However , further studies are warranted to substantiate the present findings
Meta- analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to reduce both the risk of severe asthma exacerbation and healthcare use .
Children and people with frequent severe asthma exacerbations were under-represented ; additional primary trials are needed to establish whether vitamin D can reduce the risk of severe asthma exacerbation in these groups
BACKGROUND Several clinical trials of vitamin D to prevent  asthma exacerbation  and improve  asthma control  have been conducted in children and adults , but a meta- analysis restricted to double-blind , r and omised , placebo-controlled trials of this intervention is lacking .
OBJECTIVES To evaluate the efficacy of administration of vitamin D and its hydroxylated metabolites in reducing the risk of severe asthma exacerbations ( defined as those requiring treatment with systemic corticosteroids ) and improving asthma symptom control .